Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) was the recipient of a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 49,000 shares, a growth of 438.5% from the August 30th total of 9,100 shares. Based on an average trading volume of 77,400 shares, the short-interest ratio is presently 0.6 days. Approximately 0.4% of the shares of the company are short sold.
A hedge fund recently bought a new stake in Hancock Jaffe Laboratories stock. Jane Street Group LLC purchased a new stake in shares of Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 77,915 shares of the company’s stock, valued at approximately $81,000. Jane Street Group LLC owned approximately 0.43% of Hancock Jaffe Laboratories at the end of the most recent quarter. Hedge funds and other institutional investors own 1.29% of the company’s stock.
Hancock Jaffe Laboratories stock opened at $0.66 on Friday. Hancock Jaffe Laboratories has a twelve month low of $0.64 and a twelve month high of $3.45. The firm has a 50 day moving average price of $0.91 and a 200-day moving average price of $1.39. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.46 and a quick ratio of 2.46.
A number of research analysts have recently weighed in on the stock. Maxim Group reissued a “buy” rating and set a $3.00 target price on shares of Hancock Jaffe Laboratories in a research report on Thursday, August 15th. Zacks Investment Research downgraded shares of Hancock Jaffe Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, June 26th. Finally, ValuEngine downgraded shares of Hancock Jaffe Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday, September 26th.
About Hancock Jaffe Laboratories
Hancock Jaffe Laboratories, Inc, a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease.
Featured Article: What is the QQQ ETF?
Receive News & Ratings for Hancock Jaffe Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hancock Jaffe Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.